Frost & Sullivan independent industry report identifies PromarkerD as the world leading test for Diabetic Kidney Disease
PERTH, W AUSTRALIA, Mar 28, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in predictive diagnostics for diabetic kidney disease, according to an independent Frost & Sullivan report released this month. PILL managing director Dr Richard Lipscombe is in Shanghai this week meeting with possible commercialisation partners for China, and was showcasing PromarkerD at the China-Australia Biotech Investment forum in Shanghai today.
| Managing Director Dr Richard Lipscombe, PILL Laboratories, Harry Perkins Institute of Medical Research, Perth, Western Australia. |
Dr Lipscombe said the new report, titled Biomarkers Enabling Diabetes and Obesity Management, identifies PromarkerD as the world leader. The report says novel biomarker research is likely to transform the future of obesity and diabetes management.
Frost & Sullivan states that novel tools like PromarkerD can allow enhanced management of obesity, diabetes and related complications in the near future, and goes on to highlight PILL's novel test for diabetic kidney disease noting its high adoption potential.[1]
PromarkerD technology has also been validated by the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).[2]
There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggest PILL is one of only two companies worldwide developing such a test. Results have shown PromarkerD can correctly predict 95% of previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.
PILL already has a deal in place with Chinese biopharmaceutical company Newsummit Biopharma Co. (NSB) to manufacture the PromarkerD kit in China. The process includes engagement of Key Opinion Leaders and Hospitals, who will facilitate validation of the completed kit.
Publication details [1] 'Biomarkers Enabling Diabetes and Obesity Management' published by Frost & Sullivan, March 2, 2017. [2] 'Comprehensive Mass Spectrometry Based Biomarker Discovery and Validation Platform as Applied to Diabetic Kidney Disease' published in EuPA Open Proteomics, the official journal of the European Proteomics Association, March 1, 2017. - Publication materials available at http://bit.ly/2nqMfNY
Multimedia Presentation: An audio summary of the research paper. Video: The power of the Promarker platform for personalised medicine. - MultiMedia support available at http://bit.ly/2nqMfNY
PromarkerD - a predictive diagnostic test for diabetic kidney disease --
The EuPA journal article followed evaluation by independent scientific experts and serves to verify the process used to develop and test PILL's PromarkerD protein 'fingerprint' that measures kidney disease in patients with diabetes. This novel test can both diagnose and predict disease.
In diabetic patients already suffering from chronic kidney disease PromarkerD could diagnose the presence of disease that was missed by the current gold standard tests (known as the ACR and eGFR tests).
Critically, PromarkerD can also predict the onset of disease before clinical symptoms appear. In an extension of the published work 576 patients were followed in a four-year longitudinal clinical study. PromarkerD correctly predicted 95% of the previously kidney disease-free diabetic patients who went on to develop chronic kidney disease.
About the Promarker Platform --
PILL's diagnostic research is made possible by the company's proprietary biomarker discovery platform termed Promarker, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing.
The technology is so versatile it can be used to identify fingerprints from any biological source. The Promarker platform is also being applied to the asbestos-related cancer mesothelioma, the gastro-causing parasite Giardia (in partnership with a US veterinary company) and endometriosis, a condition that affects one in ten women in their reproductive years.
About Proteomics International Laboratories (PILL) --
PILL (ASX: PIQ) is a medical technology company focused on proteomics - the industrial scale study of the structure and function of proteins. As proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems, proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.
PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.
The Company's business model uses its proprietary technology platform across three integrated areas, each massive growth markets:
1. Diagnostics: Biomarkers of disease and personalised medicine - focus on diabetic kidney disease. By 2020 the biomarkers market is estimated to double in size to $45.6 billion, and the personalised medicine market is forecast to be worth over $149 billion. 2. Analytical services: Specialist contract research fee-for-service model - focus on biosimilars QC. The global biosimilars market is expected to reach $6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent. 3. Drug discovery: Therapeutic peptide drug discovery - focus on painkillers and antibiotics. The global peptide therapeutics market is currently estimated to be worth $18 billion and is expected to increase by over 10% per year during 2016-2025.
For further information, please visit www.proteomics.com.au, or contact:
Dr Richard Lipscombe Managing Director, Proteomics International Laboratories Ltd E: enquiries@proteomics.com.au T: +61 2 8218 2144
Media Contact: Susan Fitzpatrick-Napier Digital Mantra Group E: team@dmgpr.com T: +61 8 9389 1992
Source: Proteomics International Laboratories Ltd (PILL) Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan Apr 26, 2024 10:00 JST
| Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024 Apr 25, 2024 18:21 JST
| MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park Apr 25, 2024 17:45 JST
| GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series Apr 25, 2024 16:50 JST
| Toyota Exhibiting at Beijing Motor Show 2024 Apr 25, 2024 16:25 JST
| Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada Apr 25, 2024 11:10 JST
| UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh Apr 25, 2024 09:00 JST
| Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date Apr 24, 2024 17:19 JST
| MC and Denka Sign J/V Agreement in Fullerene Business Apr 24, 2024 17:02 JST
| Mitsubishi Motors Posts Record Sales in the Philippines in FY2023 Apr 24, 2024 13:56 JST
| NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance Apr 24, 2024 13:25 JST
| Fujitsu SX Survey reveals key success factors for sustainability Apr 23, 2024 10:25 JST
| Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions Apr 22, 2024 16:09 JST
| NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II Apr 22, 2024 15:09 JST
| Soft Space Launches the First and Only JCB Payment Gateway in Malaysia Apr 22, 2024 15:00 JST
| TOYOTA GAZOO Racing takes a one-two in Croatian thriller Apr 22, 2024 10:47 JST
| First-ever Mazda CX-80 Crossover SUV Unveiled in Europe Apr 19, 2024 13:50 JST
| Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces Apr 19, 2024 10:17 JST
| Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas Apr 18, 2024 17:01 JST
| Toyota Launches All-New Land Cruiser "250" Series in Japan Apr 18, 2024 13:39 JST
|
More Latest Release >>
|